Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07538804 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Avistone Biotechnology Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 294
- Enrollment target
NCT07538804: Recruiting Phase 1 study, sponsored by Avistone Biotechnology Co..
NCT07538804 is a Phase 1 study that is actively recruiting participants, run by Avistone Biotechnology Co.. The registered enrollment target is 294 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (390% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07538804, a Phase 1 study, is actively recruiting participants, sponsored by Avistone Biotechnology Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 294 participants
- Enrollment target
Study Summary
This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.
Primary Outcome
Number of patients with adverse events by system organ class and preferred term
Interventions
- DRUG ANS02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2026-07-10 |
| Est. Completion | 2029-10-30 |
| Phase | Phase 1 |
What NCT07538804 shows while recruiting
NCT07538804 is an interventional study that assigns participants to a tested intervention. The registered 294 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (390% higher).
The record links to 0 conditions, and to 1 intervention - of which ANS02 is the first listed.
NCT07538804 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07538804 about?
NCT07538804 is a clinical study titled "A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer". This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.
What is the current status of trial NCT07538804?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 294 participants. The study started on 2026-07-10. Estimated completion is 2029-10-30.
What interventions are being tested in trial NCT07538804?
The interventions under investigation include: ANS02 (DRUG).
Who is sponsoring clinical trial NCT07538804?
This trial is sponsored by Avistone Biotechnology Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07538804's enrollment target sits among peer trials
294 135th of 2000 higher than 1,865 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05775159 · 294 participants · Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- NCT06262113 · 294 participants · NA
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
- NCT06338865 · 294 participants · NA
Short Title: Standard vs. Lower Pressure Pneumoperitoneum
- NCT06395467 · 294 participants · NA
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI